What are IOVA's recent SEC filings?
Iovance Biotherapeutics filed a routine Form 8-K cover page with no substantive corporate event disclosed.
View full filing details →Iovance Biotherapeutics filed its quarterly report on Form 10-Q for the period ending September 30, 2026, reporting financial results and operational updates.
View full filing details →Iovance Biotherapeutics filed an 8-K to disclose an updated corporate presentation (Exhibit 99.1) for use at healthcare conferences and with analysts and investors. The filing contains no material financial or operational news beyond the routine presentation update.
View full filing details →Iovance Biotherapeutics filed a routine Form 8-K cover page with the SEC on October 29, 2026, containing only standard registrant identification and XBRL metadata with no substantive corporate event disclosed.
View full filing details →Iovance Biotherapeutics filed a routine Form 8-K cover page with no substantive event disclosed in the provided text.
View full filing details →Iovance Biotherapeutics, Inc. filed an 8-K form with the SEC on September 29, 2026, reporting a change in its principal executive offices from San Carlos, CA to Philadelphia, PA.
View full filing details →Has IOVA ever done a stock split?
No stock splits are recorded for IOVA.
What is IOVA's share float?
Get Real-Time IOVA Intelligence
SEPT X-Ray combines SEC filings with price targets, support/resistance levels, and smart money tracking — updated every 30 minutes.
Try SEPT X-Ray Free